Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, RoslinCT will manufacture the world’s first CRISPR-based therapy, exa-cel (exagamglogene autotemcel), a new treatment for sickle cell disease and transfusion-dependent beta thalassemia, across the world for Vertex.
Product Name : Exa-cel
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 28, 2023
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
